Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

RBOT - Vicarious Surgical Inc. Последние новости | Finranks

Home

RBOT

V

Vicarious Surgical Inc. (RBOT)

OID – Цена в реальном времени. Валюта: USD

0.71

-0.14 (-16.47%)

При закрытии: Mar 27, 2026, 3:52 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing

Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing

WALTHAM, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced that it has received approval for its Class A common stock to upgrade to the OTCQB® Venture Market by OTC Markets Group Inc. (the “OTCQB”).

Vicarious Surgical Announces Strategic Plan to Pursue Nasdaq Listing

Vicarious Surgical Announces Strategic Plan to Pursue Nasdaq Listing

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (OTCID: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery, today announced a series of strategic actions intended to strengthen the Company's financial position, enhance trading liquidity, and support a potential relisting of its common stock on a national exchange. Over the past several months, Vicarious Surgical has implemented significant operational and cost discipline initiatives des.

Vicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial Results

Vicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCID: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Results Total operating expenses were $9.3 million in the fourth quarter of 2025, and $15.0 million in the fourth quarter of 2024, a decrease of 38%. Researc.

Vicarious Surgical Receives Delisting Notice From NYSE

Vicarious Surgical Receives Delisting Notice From NYSE

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the “Common Stock”). Trading on the Company's Common Stock on the NYS.

NYSE to Commence Delisting Proceedings Against Vicarious Surgical Inc. (RBOT)

NYSE to Commence Delisting Proceedings Against Vicarious Surgical Inc. (RBOT)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the Class A common stock of Vicarious Surgical Inc. (the “Company”) — ticker symbol RBOT — from the NYSE. Trading in the Company's Class A common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company's Class A common stock pursuant to Section 802.01B of the NYSE's Listed Compan.

Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed.

RBOT Enters Strategic Software Partnership to Streamline Development

RBOT Enters Strategic Software Partnership to Streamline Development

Vicarious Surgical inks a software execution partnership to streamline development, cut costs and improve predictability.

Видео

No Data

There is no data to display

Пресс-релизы

Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing

Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing

WALTHAM, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced that it has received approval for its Class A common stock to upgrade to the OTCQB® Venture Market by OTC Markets Group Inc. (the “OTCQB”).

Vicarious Surgical Announces Strategic Plan to Pursue Nasdaq Listing

Vicarious Surgical Announces Strategic Plan to Pursue Nasdaq Listing

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (OTCID: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery, today announced a series of strategic actions intended to strengthen the Company's financial position, enhance trading liquidity, and support a potential relisting of its common stock on a national exchange. Over the past several months, Vicarious Surgical has implemented significant operational and cost discipline initiatives des.

Vicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial Results

Vicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCID: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Results Total operating expenses were $9.3 million in the fourth quarter of 2025, and $15.0 million in the fourth quarter of 2024, a decrease of 38%. Researc.

Vicarious Surgical Receives Delisting Notice From NYSE

Vicarious Surgical Receives Delisting Notice From NYSE

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the “Common Stock”). Trading on the Company's Common Stock on the NYS.